PCNA Response: Tact Trial, ACC.13 Scientific Sessions
Sunday, 10 March 2013 14:49
SAN FRANCISCO, March 10, 2013
The Trial to Assess Chelation Therapy (TACT), presented on Sunday at the American College of Cardiology 2013 Scientific Sessions, revealed results of partnering high-dose vitamins with chelation therapy for a primary endpoint of impacting total mortality, recurrent myocardial infarction, stroke, coronary revascularization, and hospitalization for angina.
“The NIH funded trial did show some benefit of chelation therapy and high-dose vitamins but some non-adherence was noted,” states Barbara Fletcher, RN, MN, FAHA, FPCNA, FAAN from the University of North Florida, Jacksonville and incoming president-elect on the Preventive Cardiovascular Nurses Association (PCNA) board of directors.
“This data is of interest, but we must continue to practice evidence-based guideline therapy. Future research with high-dose vitamins and chelation therapy is warranted.”
Contact: Abby Despins, 920-606-2115, firstname.lastname@example.org